Advisory Committees

February 28, 2014: Vaccines and Related Biological Products Advisory Committee Meeting Final Agenda

Food and Drug Administration
Center for Biologics Evaluation and Research
Vaccines and Related Biological Products Advisory Committee
135th Meeting
FDA White Oak Campus, Bldg 31, Great Room
Silver Spring, Maryland
February 28, 2014

8:00 a.mCall to Order and Opening Remarks
Introduction of Committee
Robert Daum, M.D.
Conflicts of Interest StatementPrabha Atreya, Ph.D. 
Designated Federal Officer, VRBPAC
Topic I: Presentation of Laboratory of Respiratory Viral Diseases, Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research
8:15 a.m.Overview of the CBER and OVRR Research and Site Visit processCarolyn Wilson, Ph.D.
Associate Director for Research
8:45 a.m.Overview of the Division of Viral Products & Laboratory of Respiratory Viral DiseasesJerry Weir, Ph.D.
Division of Viral Products and Acting Chief, LRVD
9:30 a.m.Closed Session
10:00 a.m.Break
Topic II:  Strain Selection for the Influenza Virus Vaccine for the 2014-2015 Influenza Season
10:30 a.m.Conflict of Interest StatementPrabha Atreya, Ph.D.
Designated Federal Officer
10:45 a.m.Influenza Virus Vaccine 2014-2015 Strain SelectionJerry Weir, Ph.D.
Division of Viral Products
10:55 a.m.U.S. Surveillance and Influenza Activity UpdateLisa Grohskopf, M.D.
Associate Chief for Policy & Liaison Activities, Epidemiology & Prevention Branch, Influenza Division, CDC
11:15 a.m.Global Surveillance/Virus CharacterizationNancy Cox, Ph.D.
Director, Influenza  Division
Director, WHO Collaborating Center
Center for Surveillance, Epidemiology and Control of Influenza, and National Center for Immunization & Respiratory Diseases, CDC
12:00 p.m.DoD Surveillance and Vaccine EffectivenessCAPT Michael J. Cooper, Ph.D.
Leader, Respiratory Pillar Activities
Division of GEIS
Armed Forces Health Surveillance Center
12:20 p.m.Lunch
1:20 p.m.Influenza Vaccine ResponsesZhiping Ye, M.D., Ph.D.
Senior Investigator
Division of Viral Products
1:40 p.m.Candidate Vaccine Strains & Potency ReagentsManju Joshi, Ph.D.
Lead Biologist
Division of Biological Standards & Quality Control,
2:00 p.m.Influenza Vaccine Manufacturing: Industry PerspectiveSam Lee, Ph.D.
Senior Director, Pandemic Influenza Strategy
Sanofi Pasteur
2:20 p.m.Open Public Hearing
3:20 p.m.Committee Discussion and Recommendations
4:20 p.m.Adjourn

Page Last Updated: 08/24/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English